<DOC>
	<DOCNO>NCT02547844</DOCNO>
	<brief_summary>To compare lipidomic profile patient HIV-1 viral suppression change efavirenz + emtricitabine + tenofovir ( Atripla ) rilpivirine + emtricitabine + tenofovir ( Eviplera® ) versus group patient continue Atripla® .</brief_summary>
	<brief_title>Evolution Plasma Lipid Profile Patients With HIV1 Who Change Atripla Eviplera Compared Continue With Atripla</brief_title>
	<detailed_description />
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Patients age 18 year Patients infect HIV1 Patients treat Atripla least last 6 month . Patients virologic suppression ( HIV RNA &lt; 50 copy / ml ) least last 6 month . Women childbearing potential must use contraception double barrier . Voluntary signature inform consent Any acute chronic ( besides chronic HIV1 ) disease could interfere analysis lipidomic Women pregnant lactating Abuse alcohol drug Body Mass Index ( BMI ) &gt; 25 Use drug may affect lipid metabolism ( lipidlowering drug , steroid ... ) Patients unable understand study protocol condition investigator 's opinion could jeopardize compliance protocol History presence allergy study drug component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>